CU20130110A7 - Composiciones vacunales bivalentes y su uso para la terapia de tumores - Google Patents

Composiciones vacunales bivalentes y su uso para la terapia de tumores

Info

Publication number
CU20130110A7
CU20130110A7 CU2013000110A CU20130110A CU20130110A7 CU 20130110 A7 CU20130110 A7 CU 20130110A7 CU 2013000110 A CU2013000110 A CU 2013000110A CU 20130110 A CU20130110 A CU 20130110A CU 20130110 A7 CU20130110 A7 CU 20130110A7
Authority
CU
Cuba
Prior art keywords
vaccine compositions
tumor therapy
tumor
bivalent vaccine
vssp
Prior art date
Application number
CU2013000110A
Other languages
English (en)
Other versions
CU24299B1 (es
Inventor
Ramírez Belinda Sánchez
Rivera Arianna Yglesias
Pérez Amelia Gutiérrez
Suárez Narjara González
Original Assignee
Ct De Inmunología Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51453541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20130110(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct De Inmunología Molecular filed Critical Ct De Inmunología Molecular
Priority to CUP2013000110A priority Critical patent/CU24299B1/es
Priority to UAA201602000A priority patent/UA116154C2/uk
Priority to ARP140102872A priority patent/AR097172A1/es
Priority to AU2014298978A priority patent/AU2014298978B2/en
Priority to TW103126421A priority patent/TWI554281B/zh
Priority to CA2916552A priority patent/CA2916552C/en
Priority to TN2015000557A priority patent/TN2015000557A1/en
Priority to EA201690309A priority patent/EA034194B1/ru
Priority to SG11201600084WA priority patent/SG11201600084WA/en
Priority to KR1020167000152A priority patent/KR20160018665A/ko
Priority to PE2016000083A priority patent/PE20160174A1/es
Priority to MX2016001459A priority patent/MX2016001459A/es
Priority to JP2016530348A priority patent/JP6479002B2/ja
Priority to PCT/CU2014/000004 priority patent/WO2015014327A1/es
Priority to NZ716579A priority patent/NZ716579B2/en
Priority to ES14758073T priority patent/ES2894075T3/es
Priority to MYPI2016700376A priority patent/MY194889A/en
Priority to EP14758073.2A priority patent/EP3028714B1/en
Priority to US14/908,635 priority patent/US20160166667A1/en
Priority to CN201480042561.6A priority patent/CN105407916A/zh
Priority to BR112016002174-6A priority patent/BR112016002174B1/pt
Publication of CU20130110A7 publication Critical patent/CU20130110A7/es
Priority to CL2015003706A priority patent/CL2015003706A1/es
Priority to IL243879A priority patent/IL243879B/en
Priority to PH12016500224A priority patent/PH12016500224A1/en
Priority to ZA2016/01328A priority patent/ZA201601328B/en
Priority to HK16108330.4A priority patent/HK1220141A1/zh
Publication of CU24299B1 publication Critical patent/CU24299B1/es
Priority to US16/398,334 priority patent/US20190275132A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen composiciones vacunales que combinan en igual proporción los dominios extracelulares de los receptores de factores de crecimiento Her1 y Her2 o fragmentos de estos y adicionalmente proteoliposomas de uy pequeña talla derivado de proteínas de la membrana externa de Neisseria meningitidis y el gangliósido GM3 ( VSSP- GM3), que están destinadas a la administración subcutánea. Las composiciones descritas permiten inducir anticuerpos para el tratamiento de tumores malignos y presentan ventajas debido a que logran eliminar totalmente la masa tumoral y evitan la regresión del tumor a partir de la aparición de variantes resistentes.
CUP2013000110A 2013-08-02 2013-08-02 Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico CU24299B1 (es)

Priority Applications (27)

Application Number Priority Date Filing Date Title
CUP2013000110A CU24299B1 (es) 2013-08-02 2013-08-02 Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
UAA201602000A UA116154C2 (uk) 2013-08-02 2014-01-08 Бівалентна вакцинна композиція та її застосування для лікування злоякісних пухлин
ARP140102872A AR097172A1 (es) 2013-08-02 2014-07-31 Composiciones vacunales bivalentes y su uso para la terapia de tumores
BR112016002174-6A BR112016002174B1 (pt) 2013-08-02 2014-08-01 Composição de vacina
JP2016530348A JP6479002B2 (ja) 2013-08-02 2014-08-01 二価ワクチン組成物及び腫瘍を治療するためのその使用
MYPI2016700376A MY194889A (en) 2013-08-02 2014-08-01 Divalent vaccine compositions and the use thereof for treating tumors
CA2916552A CA2916552C (en) 2013-08-02 2014-08-01 Divalent vaccine compositions and the use thereof for treating tumors
TN2015000557A TN2015000557A1 (en) 2013-08-02 2014-08-01 Divalent vaccine compositions and the use thereof for treating tumours
EA201690309A EA034194B1 (ru) 2013-08-02 2014-08-01 Вакцинная композиция и ее применение для лечения злокачественных опухолей
SG11201600084WA SG11201600084WA (en) 2013-08-02 2014-08-01 Divalent vaccine compositions and the use thereof for treating tumours
KR1020167000152A KR20160018665A (ko) 2013-08-02 2014-08-01 이가 백신 조성물 및 종양 치료를 위한 이의 용도
PE2016000083A PE20160174A1 (es) 2013-08-02 2014-08-01 Composiciones vacunales bivalentes y su uso para la terapia de tumores
MX2016001459A MX2016001459A (es) 2013-08-02 2014-08-01 Composiciones vacunales bivalentes y su uso para la terapia de tumores.
AU2014298978A AU2014298978B2 (en) 2013-08-02 2014-08-01 Divalent vaccine compositions and the use thereof for treating tumours
PCT/CU2014/000004 WO2015014327A1 (es) 2013-08-02 2014-08-01 Composiciones vacunales bivalentes y su uso para la terapia de tumores
NZ716579A NZ716579B2 (en) 2013-08-02 2014-08-01 Divalent vaccine compositions and the use thereof for treating tumours
ES14758073T ES2894075T3 (es) 2013-08-02 2014-08-01 Composiciones de vacunas divalentes y el uso de las mismas para el tratamiento de tumores
TW103126421A TWI554281B (zh) 2013-08-02 2014-08-01 二價疫苗組成物及彼於腫瘤治療上之用途
EP14758073.2A EP3028714B1 (en) 2013-08-02 2014-08-01 Divalent vaccine compositions and the use thereof for treating tumours
US14/908,635 US20160166667A1 (en) 2013-08-02 2014-08-01 Divalent vaccine compositions and the use thereof for treating tumors
CN201480042561.6A CN105407916A (zh) 2013-08-02 2014-08-01 二价疫苗组合物以及其用于治疗肿瘤的用途
CL2015003706A CL2015003706A1 (es) 2013-08-02 2015-12-22 Composiciones vacunales bivalentes y su uso para la terapia de tumores
IL243879A IL243879B (en) 2013-08-02 2016-01-31 Bivalent vaccines and their use for the treatment of tumors
PH12016500224A PH12016500224A1 (en) 2013-08-02 2016-02-02 Divalent vaccine compositions and the use thereof for treating tumors
ZA2016/01328A ZA201601328B (en) 2013-08-02 2016-02-26 Divalent vaccine compositions and the use thereof for treating tumors
HK16108330.4A HK1220141A1 (zh) 2013-08-02 2016-07-15 二價疫苗組合物以及其用於治療腫瘤的用途
US16/398,334 US20190275132A1 (en) 2013-08-02 2019-04-30 Divalent vaccine compositions and the use thereof for treating tumors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CUP2013000110A CU24299B1 (es) 2013-08-02 2013-08-02 Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico

Publications (2)

Publication Number Publication Date
CU20130110A7 true CU20130110A7 (es) 2015-03-30
CU24299B1 CU24299B1 (es) 2017-12-08

Family

ID=51453541

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2013000110A CU24299B1 (es) 2013-08-02 2013-08-02 Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico

Country Status (24)

Country Link
US (2) US20160166667A1 (es)
EP (1) EP3028714B1 (es)
JP (1) JP6479002B2 (es)
KR (1) KR20160018665A (es)
CN (1) CN105407916A (es)
AR (1) AR097172A1 (es)
AU (1) AU2014298978B2 (es)
CA (1) CA2916552C (es)
CL (1) CL2015003706A1 (es)
CU (1) CU24299B1 (es)
EA (1) EA034194B1 (es)
ES (1) ES2894075T3 (es)
HK (1) HK1220141A1 (es)
IL (1) IL243879B (es)
MX (1) MX2016001459A (es)
MY (1) MY194889A (es)
PE (1) PE20160174A1 (es)
PH (1) PH12016500224A1 (es)
SG (1) SG11201600084WA (es)
TN (1) TN2015000557A1 (es)
TW (1) TWI554281B (es)
UA (1) UA116154C2 (es)
WO (1) WO2015014327A1 (es)
ZA (1) ZA201601328B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018166542A1 (es) * 2017-03-15 2018-09-20 Centro De Inmunologia Molecular Método para el tratamiento de pacientes con carcinomas
US12019073B2 (en) 2017-03-15 2024-06-25 Centro De Inmunologia Molecular Method for the treatment of patients with carcinomas
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4306697A1 (de) * 1993-03-04 1994-09-08 Merck Patent Gmbh Mittel und Verfahren zur immunologischen Bestimmung von Diphenhydramin und dessen Metaboliten
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
EP2639299A1 (en) * 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase

Also Published As

Publication number Publication date
EP3028714B1 (en) 2021-09-29
CN105407916A (zh) 2016-03-16
UA116154C2 (uk) 2018-02-12
EA034194B1 (ru) 2020-01-16
PE20160174A1 (es) 2016-04-20
HK1220141A1 (zh) 2017-04-28
IL243879B (en) 2019-09-26
TN2015000557A1 (en) 2017-04-06
MY194889A (en) 2022-12-21
PH12016500224A1 (en) 2016-05-16
BR112016002174A2 (pt) 2017-08-01
ES2894075T3 (es) 2022-02-11
EP3028714A1 (en) 2016-06-08
AU2014298978B2 (en) 2019-05-23
IL243879A0 (en) 2016-04-21
TWI554281B (zh) 2016-10-21
KR20160018665A (ko) 2016-02-17
AR097172A1 (es) 2016-02-24
TW201521765A (zh) 2015-06-16
SG11201600084WA (en) 2016-02-26
NZ716579A (en) 2021-10-29
JP2016525555A (ja) 2016-08-25
US20160166667A1 (en) 2016-06-16
EA201690309A1 (ru) 2016-06-30
MX2016001459A (es) 2017-01-05
CU24299B1 (es) 2017-12-08
CL2015003706A1 (es) 2016-07-22
JP6479002B2 (ja) 2019-03-06
US20190275132A1 (en) 2019-09-12
ZA201601328B (en) 2017-11-29
CA2916552C (en) 2020-03-31
CA2916552A1 (en) 2015-02-05
WO2015014327A1 (es) 2015-02-05
AU2014298978A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
BR112016025035A2 (pt) imunoterapia contra diversos tumores hematológicos, como a leucemia mieloide aguda (aml)
PE20080663A1 (es) Terapia tumoral con una combinacion de anticuerpos anti-her2
CR20160018A (es) Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)
CY1118608T1 (el) Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6
BR112017008972A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia contra carcinoma hepatocelular (hcc) e outros cânceres
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
BR112016009402A2 (pt) Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
ECSP088753A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
WO2014168548A3 (en) Therapeutic delivery vesicles
BR112013029834A2 (pt) vacinas individualizadas para câncer
BR112012030479A2 (pt) terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1
CY1122453T1 (el) Νεα ανοσοθεραπεια εναντι διαφορων ογκων, οπως καρκινος του πνευμονα, οπου συμπεριλαμβανεται nsclc
AR075982A1 (es) Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
AR097172A1 (es) Composiciones vacunales bivalentes y su uso para la terapia de tumores
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
BR112018072988A2 (pt) irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
EA201691385A1 (ru) Комбинированная терапия рака
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes
BR112015022010A2 (pt) Uso de sdf-1 para mitigar a formação de cicatrizes
NZ625758A (en) Method for treating breast cancer
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas